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Abstract
Spleen tyrosine kinase (SYK) is an important oncogene and signaling mediator activated by cell surface receptors
crucial for acute myeloid leukemia (AML) maintenance and progression. Genetic or pharmacologic inhibition of SYK
in AML cells leads to increased differentiation, reduced proliferation, and cellular apoptosis. Herein, we addressed
the consequences of SYK inhibition to leukemia stem-cell (LSC) function and assessed SYK-associated pathways in
AML cell biology. Using gain-of-function MEK kinase mutant and constitutively active STAT5A, we demonstrate that
R406, the active metabolite of a small-molecule SYK inhibitor fostamatinib, induces differentiation and blocks
clonogenic potential of AML cells through the MEK/ERK1/2 pathway and STAT5A transcription factor, respectively.
Pharmacological inhibition of SYK with R406 reduced LSC compartment defined as CD34+CD38−CD123+ and
CD34+CD38−CD25+ in vitro, and decreased viability of LSCs identified by a low abundance of reactive oxygen
species. Primary leukemic blasts treated ex vivo with R406 exhibited lower engraftment potential when
xenotransplanted to immunodeficient NSG/J mice. Mechanistically, these effects are mediated by disturbed
mitochondrial biogenesis and suppression of oxidative metabolism (OXPHOS) in LSCs. These mechanisms appear to
be partially dependent on inhibition of STAT5 and its target gene MYC, a well-defined inducer of mitochondrial
biogenesis. In addition, inhibition of SYK increases the sensitivity of LSCs to cytarabine (AraC), a standard of AML
induction therapy. Taken together, our findings indicate that SYK fosters OXPHOS and participates in metabolic
reprogramming of AML LSCs in a mechanism that at least partially involves STAT5, and that SYK inhibition targets
LSCs in AML. Since active SYK is expressed in a majority of AML patients and confers inferior prognosis, the
combination of SYK inhibitors with standard chemotherapeutics such as AraC constitutes a new therapeutic
modality that should be evaluated in future clinical trials.
Introduction
Acute myeloid leukemia (AML) is a heterogeneous and
aggressive malignancy characterized by uncontrolled
proliferation, increased survival, and impaired differ-
entiation of hematopoietic stem and progenitor cells1.
Despite recent approvals of new targeted agents, intensive
“3+ 7” chemotherapy with anthracycline and cytarabine
(AraC) remains the standard of care for a majority of
AML patients. Despite initial responses to this regimen,
most patients eventually relapse and long-term prognosis
for AML patients is very poor2–6. The therapy-resistant,
persistent cells that give rise to relapses are believed to
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reside in rare leukemia stem-cell (LSCs) population;
accordingly, the LSCs frequency dramatically increases
after treatment7. Therefore, targeting LSCs is a promising
therapeutic strategy in AML, potentially eliminating the
roots of the disease.
LSCs are typically characterized by their quiescent nature,
immature phenotype, distinct metabolic features, and reli-
ance on certain signaling pathways. For example, several
lines of evidence point toward an increased LSCs depen-
dence on oxidative metabolism and efficient management of
oxidative stress. Indeed, inhibition of oxidative metabolism
and/or induction of oxidative stress in LSCs leads selectively
to LSCs death8–10, indicating that these features can be
exploited therapeutically. However, cell-intrinsic signaling
circuits that induce/maintain LSCs metabolic characteristics
are less well defined. Identification of signaling pathways
responsible for metabolic reprogramming in LSCs might
provide additional therapeutic targets, perhaps with broader
therapeutic windows than direct inhibition of mitochondrial
oxidative phosphorylation (OXPHOS).
Spleen tyrosine kinase (SYK) activity and oncogenic
properties in AML were first discovered in a study inte-
grating chemical, proteomic, and genomic approaches to
identify new therapeutic strategies11,12. In AML patients, SYK
abundance and activity are associated with an unfavorable
outcome independent of age, cytogenetics, and leukocyte
count13. SYK phosphorylation and activity is induced by
multiple upstream signaling pathways critical for AML
development, including integrin signaling and FLT3-ITD,
indicating that SYK is a central signaling hub and a mediator
of multiple pathways that drive AML13–17.
Once activated, SYK regulates many downstream signaling
pathways crucial for cell survival, including mTOR and
MEK/ERK1/2, cooperates with FLT3-ITD to activate MYC
transcriptional program, and directly interacts with and
activates STAT5 and STAT3 transcription factors14–16,18,19.
Consistently, SYK inhibition with R406, an active metabolite
of FDA-approved, ATP-competitive SYK inhibitor fostama-
tinib, with less activity reported for FLT3, c-Kit, and Lck,
induces differentiation and apoptosis of leukemic cells11,20,21.
Given the activation of SYK in AML and profound
consequences of its inhibition, we dissected the role of
SYK-downstream signaling pathways in cell differentia-
tion and LSCs function. We characterize the role of SYK-
dependent MEK/ERK1/2 signaling in differentiation and
demonstrate that SYK blockade decreases mitochondrial
biogenesis and function in a mechanism involving
attenuation of STAT5 and MYC activity, leading to
decreased oxidative metabolism and LSCs death.
Results
SYK and SYK-initiated downstream signaling in AML
To better understand SYK-regulated cellular signaling
in AML, we first assessed the phosphorylation/activation
status of SYK and SYK-downstream pathways at baseline
and after incubation with R406. Tyrosine 352, associated
with SYK activation, was phosphorylated in the majority
of tested cell lines and primary patient-derived blasts
(Supplementary Fig. S1A). SYK phosphorylation was
markedly reduced by R406 in all primary AML samples
tested (n= 7) and in TEX, KG1, and MOLM14 cell lines
(Fig. 1A, B, D). Given the highest SYK activity and sen-
sitivity to R406 in TEX, KG1, and MOLM14, as compared
to other cells (Supplementary Fig. S1B), those lines were
selected for subsequent experiments. Next, we evaluated
the impact of R406 on the activity of SYK-downstream
signaling pathways ERK1/2 and STAT5, which are a part
of SYK interactome in AML14,16. In addition, we also
assessed the expression levels of MYC, a STAT5 target
gene22. Incubation with R406 dose-dependently inhibited
p-ERK1/2T202/Y204, p-STAT5Y694, and decreased MYC
levels (Fig. 1C) in AML cells lines, and decreased p-ERK1/
2T202/Y204 and p-STAT5Y694 in primary AML blasts
(Fig. 1D). Of note, P505 and entospletinib, inhibitors
highly specific for SYK, phenocopied the results obtained
with R406 in KG1, MOLM14, and TEX cells (Supple-
mentary Fig. S1F, G). In line with these findings, gene set
enrichment analysis (GSEA) of publicly available micro-
array data15 revealed that multiple components of IL2-
STAT5 signaling and MYC target genes were among the
most downregulated gene sets in AML cell lines after
R406 treatment (Fig. 1E). Parallel with the reduction of
p-ERK1/2, p-STAT5, and MYC levels, SYK inhibition
profoundly decreased clonogenic potential and induced
differentiation in AML cell lines (Supplementary Fig.
S1C–E). Taken together, these results indicate that in
AML, SYK inhibition reduces the activity of its down-
stream pathways (p-ERK1/2, p-STAT5, and MYC),
induces differentiation, and reduces clonogenic potential
and viability of AML cells.
SYK signals through ERK1/2 to block differentiation of AML
cells
Since activated ERK1/2 phosphorylates CCAAT/
enhancer-binding protein α (C/EBPα) on serine 21 and
inhibits activity of this myeloid differentiation transcrip-
tion factor23, we hypothesized that the aberrant activation
of the MEK/ERK1/2 pathway through SYK might con-
tribute to the differentiation blockade in AML cells. To
test this hypothesis, we retrovirally transduced KG1 and
MOLM14 cell lines with a constitutively active form of an
upstream MEK1 kinase (MEK-DD)24,25 and assessed the
differentiation status of cells incubated either with R406
or DMSO. Consistent with previous results, in cells
expressing empty vector, R406 treatment markedly
reduced the p-ERK1/2 level, enhanced superoxide pro-
duction, increased CD14 surface level and expression of
genes involved in myeloid maturation, and increased the
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Fig. 1 R406 inhibits SYK and SYK-dependent signaling pathways in acute myeloid leukemia (AML) cells. A Representative histograms
showing SYK phosphorylation status (Tyr352) in AML cell lines (KG1, MOLM14 and TEX) at baseline and after incubation with R406 (0.2 µM, 24 h). SYK
phosphorylation was assessed by intracellular phospho-specific flow cytometry. B Quantification of changes in SYK activity from panel A. SYK Tyr352
mean fluorescence intensities (MFI) after subtracting MFI of isotype control are shown. Bars represent mean+ /− SD from two biological replicates.
C KG1, MOLM14, and TEX cells were incubated for 24 h with increasing doses of R406 (0.075 µM, 0.2 µM, 0.4 µM, 0.6 µM, 1 µM, and 4 µM). Thereafter, the
phosphorylation status of ERK1/2, STAT5, and the level of MYC protein were assessed by immunoblotting. D Primary AML blasts from seven patients
were treated with R406 (1 µM) and assessed by phosflow. pSYK, p-STAT5, and pERK MFI values of individual primary samples, after subtracting the MFI of
IgG control, before and after R406 treatment are shown. P values were calculated using paired t test. E GSEA plots showing downregulation of IL2-STAT5
components and MYC targets in KG1 and MOLM14 cell lines after R406 treatment. Data were derived from the publicly accessible dataset available from
GEO at the accession number GSE46302. FDR: false discovery rates, ES: enrichment score, NES: normalized enrichment score.
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number of cells with morphological signs of differentia-
tion (Fig. 2 and Supplementary Fig. S2). In contrast, in
MEK-DD-transduced cells, R406 only moderately
reduced the level of p-ERK1/2, and MEK-DD cells treated
with R406 did not exhibit features of differentiation
(Fig. 2A–D and Supplementary Fig. S2). These data
indicate that MEK/ERK1/2 pathway activation down-
stream of SYK plays an important role in differentiation
arrest in AML cells. Reduced MEK/ERK1/2 activity after
R406 treatment is responsible for the induction of mye-
loid maturation.
SYK-dependent p-STAT5 activity is required to maintain
the clonogenic potential of AML cells
STAT5 activity is important for the regulation of
self-renewal of hematopoietic stem cells and LSCs26–29.
Fig. 2 SYK signals through the MAPK/ERK1/2 pathway to block differentiation of leukemic cells. A KG1 and MOLM14 cells transduced with an
empty vector or a vector containing constitutively active form of MEK1 kinase (MEK-DD) were treated with R406 (KG1: 4 µM, MOLM14: 0.075 µM) for
24 h; thereafter, the phosphorylation status of ERK1/2 was assessed by immunoblotting. B Transfected cells were incubated for 3 days with R406 (KG1
0.4 µM, MOLM14 0.075 µM), and NBT reduction was assessed. The graph shows a relative change in absorbance at 620 nm. The experiment was
repeated twice. Bars indicate mean+ /− SD from biological replicates (n= 2) of a representative experiment. **P < 0.01. C May–Grunwald–Giemsa
staining of KG1 cells containing either MEK-DD or empty vector after 5 days of treatment with R406 or PMA at the indicated concentration.
Differentiated cells are morphologically characterized by nuclear condensation, increased cytoplasm/nucleus ratio, increased cell volume, and
increased number of cytoplasmic granules. D KG1 cells containing either MEK-DD or empty vector were treated with R406 (0.4 µM) for 3 days.
Thereafter, CD14 level was assessed by flow cytometry.
Polak et al. Cell Death and Disease          (2020) 11:956 Page 4 of 15
Official journal of the Cell Death Differentiation Association
Since R406 reduces STAT5 activity, we hypothesized that
in AML cells with active SYK, STAT5 might be SYK’s
downstream mediator of the stem-cell features. To test
this hypothesis, we retrovirally transduced KG1 and
MOLM14 cell lines with an empty vector or a vector
containing constitutively active form of STAT5A
(STAT5A1*6) that mediates a high level of transcription
activation independent of cytokine stimulation30,31.
Thereafter, transduced KG1 and MOLM14 cells were
incubated with R406 and colony formation in semi-solid
methylcellulose was assessed. As expected, R406 did
not block STAT5A1*6 activity, indicated by unchanged
p-STAT5Y694/699 levels (Fig. 3A). R406 treatment
decreased colony formation capacity of the empty vector
containing cells but had no significant effect on the
colony-forming ability of STAT5A1*6-expressing cells
(Fig. 3B, C). These experiments demonstrate that R406-
driven reduction of clonogenic potential in AML cells is
mediated by decreased STAT5 activity.
SYK inhibition targets LSC-enriched AML subpopulations
SYK is a critical mediator of integrin signaling in AML.
Since the loss of integrin β3 (ITGB3) downregulates LSC
transcriptional program15, we hypothesized that the loss
of SYK activity might also eliminate LSCs in AML.
Accordingly, GSEA of publicly available gene expression
datasets revealed marked and coherent downregulation of
stemness-related genes in KG1 cells after R406 treatment
(Fig. 4A). In KG1 and TEX cells treated with R406, an
abundance of LSC-enriched CD34+CD38−CD25+ and
CD34+CD38-CD123+ leukemic populations markedly
decreased, further supporting the role of SYK in LSC
maintenance32,33 (Fig. 4B, C).
Since functionally defined LSCs in AML are character-
ized by a low rate of energy metabolism and low levels of
reactive oxygen species, we further tested the R406 effects
on sorted ROS-low AML cells10. For these experiments,
we used TEX line, given its hierarchical organization
similar to normal hematopoiesis and AML34. First, TEX
cells were sorted to obtain subsets with low and high
endogenous ROS levels (ROS-low and ROS-high cells).
The stem-cell features of TEX ROS-low fraction were
confirmed by their higher colony-forming capacity and
their quiescent nature (higher fraction of G0 cells and
lower Ki-67 staining, compared to corresponding ROS-
high cells, Supplementary Fig. S3A–C). To test whether
R406 affects the viability of the LSC-enriched ROS-low
population, we exposed this leukemic fraction to
increasing doses of R406. SYK inhibition reduced pro-
liferation, clonogenic potential in the serial replating
Fig. 3 SYK-dependent p-STAT5 activity controls the clonogenic potential of acute myeloid leukemia (AML) cells. A KG1 cells were
electroporated with either an empty vector (pMIG) or a vector containing constitutively active form of STAT5 (STAT5A1*6). Forty-eight hours later,
cells were incubated with 0.4 µM R406 for additional 48 h and assessed by western blotting to determine the phosphorylation status of STAT5.
B, C KG1 or MOLM14 cells transduced with either STAT5A1*6 or an empty vector were incubated with R406 (0.4 μM) and assessed for the ability to
form colonies in methylcellulose. The graph shows the mean number of colonies+ /− SD, counted 14 days after plating (averaged data from three
independent plates). P value was calculated using Student’s t test. *P < 0.05, **P < 0.01.
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assay, and increased cell death in a dose-dependent
manner. Of note, R406 exhibited even higher toxicity in
ROS-high populations, indicating that SYK inhibition
targets LSCs and their progeny (Fig. 4D–F and Supple-
mentary Fig. S3D). P505 exhibited similar effects and
similarly decreased TEX ROS-low viability (Supplemen-
tary Fig. S4).
To further confirm that SYK inhibition targets LSCs, we
measured the ability of primary AML blasts cultured
ex vivo with R406, to engraft in immunodeficient NSG/J
mice. For this purpose, primary AML cells were cultured
with R406 or DMSO for 24 h, and 105 of viable cells were
transplanted into NSG/J mice via tail vein injection. Eight
weeks later, the mice transplanted with AML cells cul-
tured ex vivo with R406 exhibited significantly lower
fraction of leukemia cells (hCD45+hCD34+hCD33+)
within the bone marrow, when compared to mice injected
with control primary AML blasts (Fig. 4G). In a secondary
transplant, mice receiving bone marrow cells from donors
that had been inoculated with R406-pretreated AMLs
cells showed a trend to a reduced leukemia burden
(Supplementary Fig. S3E). These results further demon-
strate that SYK contributes to the maintenance of LSCs
functionality in AML.
SYK inhibition decreases mitochondrial biogenesis and
OXPHOS metabolism in AML
To gain insights into the mechanism of R406-mediated
changes in clonogenic potential and LSCs function, we
performed GSEA analysis of publicly available gene
expression datasets from AML cell lines treated with
either DMSO or R40615 and found that R406 significantly
downregulated genes related to OXPHOS (Fig. 5A). We
thus hypothesized that R406 treatment targets mito-
chondria and decreases OXPHOS metabolism in AML
cells, contributing to the elimination of LSCs. To address
this hypothesis, we assessed the differences in expression
of mitochondria biogenesis genes (MYC, nuclear
respiratory factor 1 (NRF1), transcription factor A mito-
chondrial (TFAM), and elongation factor thermo unstable
(EF-Tu)), between ROS-low and ROS-high TEX sub-
populations and found their higher expression in
Fig. 4 SYK inhibition targets leukemia stem cells (LSC)-enriched acute myeloid leukemia (AML) subpopulations. A GSEA plots showing
downregulation of stem-cell transcriptional program in KG1 and MOLM14 cell lines after R406 treatment. Source data were derived from the publicly
accessible dataset available from GEO at the accession number GSE46302. B, C KG1 and TEX cells were incubated with the indicated concentration of
R406 or P505 for 48 h, then the expression level of either CD25 or CD123 in CD34+CD38−-gated population was assessed by flow cytometry. The
experiment was repeated twice. Bars represent mean+ /− SD from two biological replicates of a representative experiment. P value was calculated
using Student’s t test. *P < 0.05, **P < 0.01, ***P < 0.001. D, E Sorted ROS-low, ROS-high and bulk TEX cells were treated with vehicle or increasing
concentration of R406 for 3 days. Thereafter, cells were analyzed by MTS assay to assess cell proliferation (D), or stained with PI followed by flow-
cytometry analysis to assess cell death (E). In D, the results are shown relative to DMSO-treated control and represent mean+ /− SD from three
biological replicates. In E, the percentage of PI-positive cells is shown. The experiment was repeated twice. Bars represent mean+ /− SD from two
biological replicates of a representative experiment. **P < 0.01, ***P < 0.001. F In total, 5 × 103 of sorted ROS-low, ROS-high, and bulk TEX cells were
plated in GFH4434 medium containing either DMSO or R406 (0.17 µM). Colonies consisting of a minimum of ten cells were counted 14 days after
plating. Graph shows the mean number of colonies (+/− SD) obtained from two independent plates. **P < 0.01. G Primary AML blasts (from patient
096/17) were cultured ex vivo for 24 h with DMSO or 4 µM of R406. Thereafter leukemia cells were transplanted into NSG/J mice (n= 5 per group).
Mice were killed 8 weeks after transplantation, and AML engraftment was assessed by FACS analysis for the presence of human CD45+CD33+CD34+
cells in mouse bone marrow. Statistical analysis was performed using Student’s t test.
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ROS-low TEX cells (Supplementary Fig. S5A). ROS-low
TEX cells also had a higher expression of mitochondrially
encoded mRNA for MT-ATP6 (a subunit of respiratory
complex V) and MT-CYB (a subunit of respiratory
complex III) (Supplementary Fig. S5A). Moreover, TEX
ROS-low cells exhibited higher mitochondrial mass than
TEX ROS-high cells (Supplementary Fig. S5B, C). Next, to
assess whether SYK inhibition impairs mitochondria
biogenesis, we incubated primary AML blasts and TEX,
KG1 and MOLM14 with R406, and assessed NRF1,
TFAM, EF-Tu, and MYC mRNA levels. R406 decreased
the expression of these genes in all tested cells (Fig. 5B
and Supplementary Fig. S5D). In line with changes in the
mRNA expression, MYC and TFAM protein levels were
markedly lower in ROS-low cells after incubation with
R406 (Fig. 5D). Importantly, R406 also blocked STAT5
activity in ROS-low cells. When compared to ROS-low
population, ROS-high cells expressed significantly lower
levels of p-STAT5 and MYC that were further reduced by
R406. However, in contrast to ROS-low cells, TFAM
levels remained unchanged in ROS-high cells treated with
R406 (Fig. 5D). Consistent with these findings, primary
Fig. 5 SYK inhibition decreases mitochondrial biogenesis and OXPHOS in acute myeloid leukemia (AML) cells. A GSEA plots showing
downregulation of genes involved in oxidative phosphorylation in KG1 and MOLM14 cell lines after R406 treatment, in the same source dataset as in
Fig. 4A and E. B The expression of MYC, NRF1, TFAM, and EF-Tu mRNA was quantified by qPCR using RNA isolated from primary AML blasts from
three patients cultured in vitro for 24 h with DMSO or R406 (1 µM). 5S RNA was used as an internal standard. Bars represent mean+ /− SD from four
technical replicates. The results are shown relative to DMSO. C Changes of mitochondrial mass in AML cells treated with R406. Primary AML blasts
from three patients, treated for 24 h with vehicle (red line) or 1 µM of R406 (blue line) were stained with Mitotracker Green FM, followed by flow-
cytometry analysis. D Sorted TEX ROS-low and TEX ROS-high cells were treated for 24 h with vehicle or indicated doses of R406 (0.6 or 1 µM) or P505
(5 µM) as indicated. Thereafter, the phosphorylation status of ERK1/2, STAT5 and MYC and TFAM protein levels were assessed by immunoblotting.
E, F Oxygen consumption rate (OCR) in TEX (1 × 105/well) and KG1 cells (75 × 103/well) after 24 h of treatment with R406 (0.6 and 0.4 μM, respectively)
was evaluated by the Seahorse XF96 extracellular flux analyzer. Arrows indicate time points of the addition of oligomycin (1 µg/mL), FCCP (TEX
1.5 µM, KG1 1.25 µM), rotenone and antimycin A mix (R/AA, 1 µM each). Values shown are the average of three (KG1) or four (TEX) independent
experiments+ /− SEM normalized to the protein level. G, H Basal respiration, maximal respiration, spare respiratory capacity, and ATP production in
TEX and KG1 cell treated as in E and F. Shown are average results of three (KG1) or four (TEX) independent experiments+ /− SEM normalized to the
protein level.
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AML blasts and TEX cells treated with R406 exhibited
decreased mitochondrial mass, as assessed by Mitotracker
staining (Fig. 5C and Supplementary Fig. S5E).
To determine whether the observed changes have
functional consequences, we assessed oxygen consump-
tion rate (OCR) in KG1 and TEX cells treated 24 h with
R406 or DMSO using Seahorse XF96 extracellular flux
analyzer. SYK inhibition severely impaired OXPHOS
metabolism in these cells, as indicated by reduced basal
and maximal OCR, reduced spare respiratory capacity,
and production of ATP (Fig. 5E–H). In contrast, SYK
inhibition did not increase extracellular acidification rate
(ECAR), indicating that these cells do not compensate
OXPHOS block by switching their energy metabolism to
glycolysis (Supplementary Fig. S5F). Of note, no increase
in cell death was observed after 24 h of treatment with
R406 (Supplementary Fig. S5J, K), indicating that
decreased cell viability was not responsible for an
observed overall reduction in metabolic activity. Taken
together, these results demonstrate that SYK inhibition
decreases mitochondrial biogenesis and oxidative meta-
bolism in AML and highlight the new role of SYK in
control of metabolic homeostasis of AML LSCs.
To ensure that the observed effects on mitochondrial
biogenesis were mediated by SYK, we silenced its
expression in TEX cells using RNAi. Having confirmed
the SYK knockdown, we assessed the expression of genes
involved in mitochondrial biogenesis and evaluated
abundance of mitochondrially encoded respiratory chain
genes. When compared to control cells, SYK-depleted
cells exhibited markedly lower MYC, NRF1, TFAM, MT-
ATP6, and MT-CYB abundance (Supplementary Fig. S5G,
H), indicating that SYK knockdown phenocopies phar-
macological inhibition of SYK in TEX cells. These results
further confirm the role of SYK as an upstream modulator
of the mitochondrial biogenesis in AML cells.
SYK-dependent p-STAT5 activity increases MYC expression
and OXPHOS metabolism in AML cells
MYC is a STAT5 target gene and a positive regulator of
mitochondrial biogenesis35. Given decreased abundance/
activity of these proteins after SYK inhibition in ROS-low
AML LSCs, we asked whether observed effects of R406 on
mitochondrial respiration are dependent on STAT5A–MYC
inhibition. To address this question, we used KG1 cells
transduced with constitutively active STAT5A1*6 construct, in
which SYK inhibition did not change STAT5 activity (Fig. 3A).
We probed these cells for MYC abundance and found that
STAT5A1*6-transduced cells had higher MYC level, when
compared to control cells. However, SYK inhibition partially
decreased MYC level in STAT5A1*6 cells, indicating that
MYC expression is at least partially independent on STAT5
(Fig. 6A). Thereafter, we measured the expression of mito-
chondrial biogenesis genes in KG1 cells transduced with
STAT5A1*6 or the empty vector, and found that active
STAT5A increased expression of TFAM, NRF1, EF-Tu, and
increased mitochondrial mass, as measured by the mito-
chondrial DNA copy number36 (Fig. 6B, C). STAT5A1*6-
transduced cells also expressed higher mRNA levels of mito-
chondrial genome-encoded MT-ATP6 and MT-CYB. Most
importantly, these cells exhibited increased OCR, indicating
augmented OXPHOS (Fig. 6D).
We next determined whether R406 impact on mito-
chondrial biogenesis and OCR (presented in Fig. 5 and
Supplementary Fig. S5) required the inhibition of STAT5
activity. For this purpose, we incubated STAT5A1*6 or
empty vector-transduced KG1 cells with R406, and
assessed the effects of this treatment on OXPHOS
metabolism and expression of genes involved in mito-
chondrial biogenesis. In control cells, R406 treatment
markedly reduced the mRNA and/or protein levels for
MYC, TFAM, EF-Tu, and NRF1. Similar changes were
observed in STAT5A1*6-expressing cells after incubation
with R406, although the expression of these genes fol-
lowing SYK inhibition remained at significantly higher
levels than in control cells (Fig. 6E). R406 reduced OCR
both in control and STAT5A1*6-expressing cells,
although in the latter, the OCR after R406 incubation also
remained higher than in controls treated in the same
manner (Fig. 6F). These findings are consistent with the
partial inhibition of MYC in STAT5A1*6-expressing cells
treated with R406 (Fig. 6A). Together, these results indi-
cate that STAT5A activity in cells with active SYK is at
least partially responsible for maintaining mitochondrial
biogenesis and OXPHOS metabolism in AML cells, and
its inhibition decreases OXPHOS. However, these results
also highlight STAT5-independent mechanisms in this
process.
R406 sensitizes ROS-low AML cells to cytarabine
LSCs are thought to be resistant to conventional
cytotoxic drugs used in standard AML treatment. As
modulation of oxidative metabolism disorders LSCs
function and characteristics, we hypothesized that SYK
inhibition would sensitize OXPHOS-dependent, ROS-
low cells to cytarabine (AraC). To test this hypothesis,
we first assessed whether TEX ROS-low and TEX ROS-
high populations have different sensitivity to AraC. As
anticipated, we found that ROS-low TEX cells were
more resistant to AraC treatment, as compared to TEX
ROS-high cells (Fig. 7). When ROS-low cells were
coincubated with R406, their sensitivity to AraC mark-
edly increased. In contrast, co-treatment of TEX ROS-
high cells with AraC and R406 did not further decrease
the viability of these cells above the level induced by
AraC alone. These observations indicate that R406-
mediated targeting of OXPHOS metabolism in LSCs
sensitizes them to AraC.
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Fig. 6 SYK-dependent p-STAT5 activity increases MYC expression, mitochondrial biogenesis, and OXPHOS. A KG1 cell were electroporated
with either empty vector (pMIG) or a vector carrying constitutively active STAT5 mutant (STAT5A1*6). Forty-eight hours later, cells were treated with
DMSO or R406 (0.4 µM) and lysed. Protein extracts were PAGE-separated and immunoblotted with anti-MYC antibody. B RNA was isolated from
KG1 cells 48 h after electroporation with STAT5A1*6 or empty vector. The basal mRNA expression level of MYC, NRF1, TFAM, EF-Tu, MT-CYB, and MT-
ATP6 was determined by qPCR using 18 s RNA as an internal standard. The experiment was repeated twice. Bars represent mean+ /− SD from four
technical replicates of a representative experiment. Data are presented relative to pMIG empty vector. **P < 0.01, ***P < 0.001. C Relative
mitochondrial DNA copy number in KG1 cell transduced with either empty vector or STAT5A1*6. DNA was extracted from cells 48 h after
electroporation, and qPCR was used to measure levels of mitochondrial ND1 gene relative to single-copy HGB gene. ND1/HGB ratio is shown relative
to an empty vector containing cells. Bars represent mean+ /− SD from four technical replicates. D Basal respiration in KG1 transduced with either
STAT5A1*6 or empty vector, as evaluated by the Seahorse XF96 extracellular flux analyzer. Five replicate wells containing 75 × 103 cells were analyzed.
Mean values normalized to protein level +/− SD are plotted. Data are presented relative to empty vector control. E KG1 cells were electroporated
with either STAT5A1*6 or empty vector and treated as described in A. Transcript levels of MYC, NRF1, TFAM, and EF-Tu were determined by qPCR
using 5 s RNA as an internal standard. The experiment was repeated twice. Bars represent mean+ /− SD from three technical replicates of a
representative experiment. Data are presented relative to empty vector-transduced, DMSO-treated cells. **P < 0.01, ***P < 0.001 as determined by
Student’s t test. F Cells were electroporated and treated as in A. Basal respiration was evaluated by the Seahorse XF96 extracellular flux analyzer. Bars
represent means of four biological replicates+ /− SD. Data are presented relative to empty vector, DMSO-treated control.
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Although AraC remains the standard of care in first-line
AML induction therapy, new targeted agents, such as
BCL2-selective inhibitor venetoclax (ABT-199), were
recently approved for AML treatment by EMA and FDA.
Since venetoclax targets LSCs in a mechanism that
involves OXPHOS inhibition8,9, we tested whether SYK
blockade would synergize with venetoclax. In KG1, TEX
and MOLM14 cells treated with ABT-199 and R406, cell
viability decreased more robustly as compared to either
drug used alone (Supplementary Fig. S6).
Discussion
SYK is an important signaling hub in AML, activated by
a number of upstream pathways. Consistent with the
kinase’s oncogenic function, genetic or chemical SYK
inhibition induces cell differentiation and death. However,
although the inhibition of SYK activity is known to
influence multiple downstream signaling pathways, their
role(s) in mediating biological consequences of SYK
blockade were incompletely understood. In this study, we
demonstrate that SYK inhibition induces AML cells
differentiation by modulation of the MEK/ERK1/2 path-
way. ERK1/2 has been found to have anti- or pro-
differentiating effects, depending on experimental condi-
tions, type, intensity, and duration of the stimulation. In
FLT3-ITD-positive AML cells, characterized by high SYK
activity14, ERK1/2 phosphorylates and inactivates the C/
EBPα, a transcription factor involved in granulocytic dif-
ferentiation23,37. Using the gain-of-function MEK kinase
mutant, which constitutively activates ERK1/2, we
demonstrate that SYK-inhibitor-induced differentiation
requires blocked MEK/ERK1/2 activity. According to this
signaling framework, inhibition of ERK1/2 might exhibit
the pro-differentiating effect at least partially through C/
EBPα, but given ERK1/2 broad substrate specificity,
connections with other pathways cannot be excluded. In a
study by Carnevale et al., the differentiation-inducing
effect of SYK inhibitor was associated with suppression of
mTOR, and simultaneous inhibition of 4E-BP1 and SYK
induced cell differentiation more efficiently than either
agent alone18. Given the cross-talk between MEK/ERK1/2
and mTOR pathways, these observations might in fact
have a common explanation. As ERK1/2 phosphorylates
p90RSK kinase, which activates mTOR38–40, the inhibi-
tion of ERK1/2 might also lead to a decreased mTOR
activity. Although our studies strongly implicate the
MEK/ERK1/2 pathway in SYK-inhibitor-induced differ-
entiation, this cascade likely plays a broader role in
mediating responses to SYK inhibitor. By using an inte-
grated proteogenomic approach, Cremer et al.41 demon-
strated that innate or acquired activation of the RAS/
MAPK/ERK1/2 signaling pathway confers resistance to
Fig. 7 SYK inhibition sensitizes OXPHOS-dependent acute myeloid leukemia (AML) cells to AraC treatment. A ROS-low, ROS-high, and bulk
TEX cells subsets were treated with DMSO, AraC (0.025 µM), R406 (0.6 µM), or combination of AraC and R406 for 72 h. Thereafter, cell death was
assessed by annexin-V/PI staining, followed by flow-cytometry analysis. Bars represent mean of two experiments+ /− SD. B Representative dotplots
of cells treated as in panel A.
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SYK inhibition, indicating that this pathway is a major
effector and reciprocal modulator of SYK-dependent
signaling in AML.
In addition to the induction of differentiation, we report
that SYK inhibition also reduced CD34+CD38−CD123+
and CD34+CD38−CD25+ compartments, and decreased
the viability of LSC-enriched ROS-low population. In line
with these observations, primary leukemic blasts treated
ex vivo with R406 exhibited lower engraftment potential
in immunocompromised NSG/J mice. Mechanistically,
these effects are mediated by SYK-inhibitor-triggered
changes in control of mitochondrial biogenesis and
metabolic function in LSCs. This self-renewing cell
population is highly susceptible to OXPHOS inhibition,
compared to bulk leukemic population10. Consistent with
the dependence on OXPHOS, LSCs have higher mito-
chondrial mass and distinct morphology (this study and
ref. 42). These observations highlight the essential role of
mitochondria for LSCs survival and indicate that LSCs
metabolic characteristics can be exploited therapeutically.
The differences in mitochondrial mass/function in
LSCs appear to be at least partially dependent on STAT5
and its target genes, including MYC, a well-defined
inducer of mitochondrial biogenesis35. In AML cell lines
with enforced expression of constitutively active STAT5,
we observed increased mRNA levels of factors regulating
mitochondrial biogenesis, including NRF1, TFAM, EF-
Tu, and MYC. Of note, shRNA-mediated inhibition of
TFAM in AML was sufficient to decrease OCR and
OXPHOS in AML cells43. Consistent with a putative
STAT5 role in the regulation of mitochondrial genome
function44, we also observed increased expression of
mitochondrial genome-encoded electron transport com-
plexes (ETC) (MT-ATP6 and MT-CYB) in cells with
active STAT5. Taken together, our findings suggest that
the SYK signaling pathway in LSCs participates in their
metabolic reprogramming in a mechanism that at least
partially involves STAT5.
Recent studies indicate that LSCs differ from the “bulk”
population also in utilizing amino acids to fuel tri-
carboxylic acid cycle9. Decreased availability or pharma-
cological inhibition of cellular import and metabolism of
amino acids with venetoclax and azacytidine impairs LSCs
survival, and produces deep and durable clinical remis-
sions8,9. Since MYC is a potent inducer of amino acid
transporters SLC7A5 and SLC1A45, and given its
decreased abundance in LSCs following SYK inhibition, it
is tempting to speculate that SYK inhibition-mediated
decrease in OCR/OXPHOS in LSCs might involve
impaired cellular amino acid import. Since MYC is par-
tially independent of STAT5 in LSCs, these observations
would explain only partial rescue effect mediated by the
introduction of constitutively active STAT5 on mito-
chondrial biogenesis and OXPHOS.
In addition to the direct effects of SYK inhibition on cell
differentiation, metabolism, and survival, SYK inhibition in
LSCs increases their sensitivity to AraC. Since LSCs can
acquire resistance to either AraC or R406, this observation
suggests that the combination therapy would be more likely to
eradicate LSCs and prevent the emergence of cells resistant to
AraC or SYK inhibitor. Residual leukemic cells that remain
after AraC therapy rewire their metabolism and boost
OXPHOS46. Similarly, cells resistant to the LSC-targeting
therapy with venetoclax and azacytidine9, reprogram their
bioenergetics, become independent of amino acid-derived
carbons, and utilize palmitate instead. These observations
highlight the unique metabolic plasticity of AML LSCs that
limit therapeutic options available upon acquisition of resis-
tance, underscoring the need to effectively target LSCs in the
first line of treatment. Sensitization of ROS-low cells to AraC
following SYK inhibition provides a starting point for further
preclinical and clinical development of such combination
therapy. Importantly, published data demonstrate that SYK
activity may be dispensable for normal hematopoiesis11,15,
suggesting that there is a therapeutic index for R406 in AML.
In fact, phase II clinical trials testing R406 for the treatment of
idiopathic thrombocytopenic purpura and rheumatoid arthri-
tis did not report significant neutropenia among the treatment
groups21,47,48.
In conclusion, our study demonstrates that SYK inhibition
in AML favors cell differentiation in MEK-ERK1/2 dependent
manner, targets LSCs through modulation of OXPHOS
metabolism and increases their sensitivity to cytarabine. As
SYK is expressed in a majority of AML cells, our study sup-
ports future clinical trials testing the combination of SYK
inhibitors with standard chemotherapeutics.
Materials and methods
Primary AML blasts and cell lines
Leukemic samples from bone marrow were obtained
after informed consent from 17 AML patients at diagnosis
or relapse. The collection and use of human tissue for this
study were approved by local Bioethics Committee Board
based on The Declaration of Helsinki. Mononuclear cells
were isolated from primary samples using density gradient
centrifugation (Ficoll-Hypaque; density 1.077 g/mL,
Sigma-Aldrich) within 24 h from harvesting. Cells were
then either cryopreserved in liquid nitrogen in the pre-
sence of 90% fetal bovine serum (FBS) (Biovest) and 10%
DMSO, or cultured at a density 1 × 106/mL in S7 medium
(83% IMDM, 15% BIT, 500 nM SR1, 500 nM UM729 (all
from StemCell Technologies), 100 ng/ml SCF, 20 ng/ml
G-CSF, 50 ng/ml FLT3-L, 20 ng/ml IL-3 (R&D), 0.1 mM
β-Mercaptoethanol, 1% penicillin/streptomycin, 1% Glu-
taMAX 1% (Lonza))49, or RPMI-1640 medium (Lonza)
containing 10% heat-inactivated FBS, 2mM L-glutamine,
10 mM HEPES, and 100 U/mL of penicillin/streptomycin,
at a density 1 × 106/mL.
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AML cells lines (KG1, MOLM14, HEL, KASUMI1,
MOLM16, U937, THP-1, OCI-AML3) were obtained
from DSMZ (Braunschweig, Germany) and cultured
according to DSMZ instructions. TEX leukemia AML cell
line was kindly provided by Prof. John E. Dick (University
Health Network (UHN), University of Toronto, Toronto,
Ontario, Canada)34. TEX cells were maintained in IMDM
(Iscove’s modified Dulbecco’s medium), 15% FBS (Sigma),
2 mM L-glutamine, 1% penicillin–streptomycin (Lonza),
20 ng/mL SCF (stem-cell factor), 2 ng/mL IL-3 (all from
R&D). 293T cells were cultured in DMEM medium
(Gibco) supplemented with 10% FBS and 100 U/ml of
penicillin/streptomycin (Lonza). All cells were kept in a
humidified incubator in 5% CO2 at 37 °C.
Chemicals
The small-molecule SYK inhibitors, R406, entospletinib
(GS-9973), PRT062607 (P505) and Venetoclax (ABT-199)
from Selleckchem, were dissolved in DMSO at 10mM,
and stored at −80 °C. Compounds were used at indicated
final concentrations. DMSO was used as a control, added
in equivalent volumes not exceeding 0.1%. Phorbol 12-
myristate 13-acetate (PMA), oligomycin, FCCP, rotenone,
and antimycin A (Sigma-Aldrich) were dissolved in
DMSO and stored at –20 °C.
Cell proliferation, cell death, and clonogenicity assays
Cells were plated in triplicates at 25,000–35,000 cells/
well in 100 μl of appropriate growth medium in a 96-well
plate and cultured in the presence of indicated con-
centrations of R406 or P505. After 72 h, cell proliferation
was assessed using MTS assay (CellTiter 96 Aqueous Non-
Radioactive Cell Proliferation Assay kit, Promega) accord-
ing to the manufacturer’s instructions. The absorbance at
490 nm was determined using a microplate reader (Mul-
tiscan GO, Thermo Scientific). For assessment of cell
death, cells were stained with Annexin-V and/or propi-
dium iodide (PI) (Annexin V apoptosis detection kit I; BD
Pharmingen) according to the manufacturer’s instructions,
and analyzed with flow cytometry and FlowJo software
(FlowJo, LLC). To assess the clonogenic potential, KG1,
MOLM14 (5 × 103), and TEX cells (35 × 103) were plated
in triplicates in GFH4434 medium (StemCell Technolo-
gies) containing either DMSO or R406 at the indicated
concentration for 14 days; thereafter, the colonies were
counted under the light microscope. For replating, cells
were pooled from duplicate plates, washed twice with PBS,
and 5 × 103 cells were replated in GFH4434 medium. After
14 days, colonies were counted under the light microscope.
Quantitative nitroblue tetrazolium reduction assay (qNBT
assay)
The ability of AML cells to produce O2
− in response to
differentiation stimuli was assessed in an NBT reduction
assay as described previously50. Briefly, after 5 days of
R406 or DMSO treatment (n= 2), AML cells (1 × 105)
were mixed (1:1) with PBS solution containing 1mg/mL
NBT (Sigma-Aldrich) and 4 µg/mL PMA (Sigma-Aldrich).
After 2 h of incubation, the cells were washed twice with
PBS, fixed with methanol, and air‐dried. Then, 120 µL of
2M NaOH was added to the cells to solubilize cell
membranes, and subsequently 140 µL of DMSO was
added to dissolve formazan deposits. After 10 min of
shaking (room temperature), the dissolved NBT solution
was transferred to a 96‐well plate, and the absorbance at
620 nm was read on a microplate reader (Multiscan GO).
Western blot analysis
Western blot analysis was performed essentially as
described previously25. Antibodies used in the study are
listed in Supplementary Table S1.
Vectors
pBabe-puro-MEK-DD (encoding MEK with phospho-
mimetic activating mutations), pBabe-puro and pMIG
were obtained from Addgene (plasmid #1526851, #176452,
and #9044, respectively). The pMIP plasmid was obtained
from pMIG trough replacement of GFP marker with
puromycin resistance gene. The cDNA encoding con-
stitutively active STAT5A form (STAT5A1*6)30 was
synthesized by ATG:biosynthetics, (Merzhausen, Ger-
many) and inserted into the BglII and XhoI sites of the
pMIG and pMIP vectors.
Retroviral transfections
VSV-G pseudotyped retrovirus was produced by
transfecting HEK 293T cells with 10 µg of either pBABE-
puro-MEK-DD, pMIP-STAT5A1*6, or appropriate empty
controls, together with the envelope (VSV-G, 5 µg) and
the packaging (pKAT, 10 µg) plasmids, using Lipofecta-
mine 2000 transfection reagent (Life Technologies) as
previously described53. After 24 h, supernatants were
harvested, filtered (0.42 µM), mixed with polybrene
(8 µg/ml) and used to infect KG1 and MOLM14 cell lines.
Seventy-two hours after infections, cells were subjected to
puromycin selection (0.5 and 0.7 μg/mL, respectively).
Electroporation
Electroporation of plasmid DNA into KG1 cells was per-
formed using Neon Transfection System MPK5000 (Invitro-
gen) and 100 µL NeonTip. Cells were plated in a complete
medium at 0.6 × 106/mL the day before electroporation.
KG1 cells (5 × 106) were electroporated with 10 µg of pMIG or
pMIG-STAT51*6 plasmid (1700V, 20ms, 1 impulse).
Quantitative real-time polymerase chain reaction (qPCR)
The total RNA was isolated from AML cells using
GeneMATRIX Universal RNA purification kit (EURx). In
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all, 1 μg of RNA was reverse-transcribed with Tran-
scriptor First-Strand cDNA synthesis kit (Roche). The
qPCR reactions were performed in triplicate with SYBR
Green Master MIX (Applied Biosystems) and gene-
specific primers (primers sequence and details are
described in Supplementary Table S2) using CFX96 qPCR
system (Bio-Rad). CT values were normalized to house-
keeping genes: GAPDH (for differentiation-associated
gene studies) or 18 s and 5 s (for expression of mito-
chondrial biogenesis genes). A relative transcript abun-
dance was quantified using the ΔΔCT method.
Mitochondrial DNA was quantified relative to the
nuclear DNA using two independent PCRs and two pairs
of primers. The first PCR amplified the NADH
dehydrogenase-1 (ND1) gene in mtDNA, while the second
PCR was used to amplify single-copy nuclear human
globulin (HGB) gene (Supplementary Table S2 and Sup-
plemental Methods).
Immunophenotyping, mitotracker staining, and flow
cytometry
Cells were washed once with PBS and stained for 30 min
at RT in the dark with fluorochrome-conjugated anti-
bodies diluted as recommended by the manufacturer
(Supplementary Table S3). Activity of SYK in primary
AML blasts and AML cell lines were assessed in 1 × 106
cells using intracellular phospho-specific flow cytometry
(Phosflow Protocol II for Human PBMCs, BD Bios-
ciences)54. To determine mitochondrial mass, cells were
incubated in PBS containing 50 nM of Mitotracker Green
FM (Thermo Scientific) for 30min at 37 °C and washed
with PBS. All FACS data were acquired on CytoFLEX
(Beckman Coulter) flow cytometer and analyzed using
FlowJo software (FlowJo, LLC).
Cell sorting based on endogenous ROS levels
In total, 50 × 106 cells were stained with the redox-
sensitive probe CM-H2DCFDA (5 µM) in PBS buffer for
15min at 37 °C in the dark. Cells were then washed with
PBS, resuspended in complete media, and incubated for
30min at 37 °C in the dark. Thereafter, AML cells with
bottom 15% or top 15% of dye fluorescence distribution
(ROS-low and ROS-high cells, respectively) were collected
using a BD ARIA II cell sorter (BD Biosciences).
Primary AML blasts ex vivo treatment and
xenotransplantations studies
All animal experiments described in this study was per-
formed in accordance with and approved by the 2nd Local
Ethical Committee for Animal Research in Warsaw, Poland.
PDX model was developed using primary AML bone marrow
blasts from a single patient (patient 096/17). Primary cells were
injected via tail vein into sublethally irradiated (2.15Gy) female
3-month-old NOD.Cg-PrkdcSCIDIl2rgtm1Wjl/J (NSG/J) mice
and after the development of overt leukemia, mice were
euthanized and bone marrow cells (BMCs) were harvested.
Following erythrocyte lysis (BD Pharm Lyse Buffer), BMCs
were cultured for 24 h in S7 medium containing either DMSO
or R406 (4 µM). After incubation, cells were washed with PBS,
and 1.75 × 106 of viable cells were resuspended in 350 μl ice-
cold PBS and re-transplanted into female NSG/J mice via tail
vein injection (n= 5 per group, no randomization). Eight
weeks after the transplantation, mice were killed and the
engraftment of human CD45+CD33+CD34+ cells in mouse
bone marrow was assessed by FACS in a blinded fashion.
Oxygen consumption rate (OCR) assessment
OCR was assessed using a Seahorse XF96 flux analyzer
(Seahorse Bioscience). KG1 (75 × 103 cells/well) and TEX
(1 × 105 cells/well) cells were cultured in a 96-well XF96
culture plate (Seahorse Bioscience) coated with BD Cell-
Tak (BD Biosciences) in their regular growth medium for
24 h with or without R406. An hour prior to the analysis,
cells were washed with PBS and resuspended in XF base
medium (pH 7.4) (Agilent Technologies) supplemented
with glucose (5 mM), L-glutamine (1.6 mM), and pyruvate
(1 mM). Plates were incubated for 1 h at 37 °C in a CO2-
free incubator and transferred to the XF96 analyzer. OCR
was measured at baseline and after the injection of oli-
gomycin (1 µg/ml), FCCP (1.5 µM for TEX and 1.25 µM
for KG1), rotenone/antimycin A (1 µM). After measure-
ments, cells were washed with PBS, lysed in 10 μL of 0.1%
Triton/PBS solution and frozen at −80 °C overnight.
Thereafter, the protein concentration in each well was
measured using BCA (Copper(II) sulfate solution and
Bicinchoninic Acid solution, Sigma-Aldrich). Data were
normalized to protein concentration and analyzed using
Wave 2.0 software (Agilent Technologies).
Gene set enrichment analysis (GSEA) and statistical
analyses
In silico data mining was performed on a gene expres-
sion dataset obtained from MOLM14 and KG1 cells
grown in 4 µM R406 for 24 h, deposited under Gene
Expression Omnibus ID GSE46302. GSEA was performed
as previously described25. All continuous data are
expressed as means, with standard deviations (SD).
Shapiro–Wilk test was used to determine normal dis-
tribution. Statistical analyses were performed using two-
sided, unpaired Student’s t test. When indicated, paired t
test was used. Differences were considered statistically
significant at P < 0.05. Sample size (n) and the number of
replicates are provided in corresponding figure legends.
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